Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum Cytokeratin 18 Fragment Is an Indicator for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease.
Kawanaka M, Kamada Y, Takahashi H, Iwaki M, Nishino K, Zhao W, Seko Y, Yoneda M, Kubotsu Y, Fujii H, Sumida Y, Kawamoto H, Itoh Y, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Kawanaka M, et al. Among authors: fujii h. Gastro Hep Adv. 2024 Aug 14;3(8):1120-1128. doi: 10.1016/j.gastha.2024.08.008. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39533978 Free PMC article.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3; STELLAR-4 Investigators. Harrison SA, et al. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147362 Clinical Trial.
Validation of Noninvasive Markers for HCC Risk Stratification in 1389 Patients With Biopsy-proven NAFLD.
Toyoda H, Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Toyoda H, et al. Among authors: fujii h. Gastro Hep Adv. 2023 Aug 2;2(8):1093-1102. doi: 10.1016/j.gastha.2023.07.018. eCollection 2023. Gastro Hep Adv. 2023. PMID: 39131553 Free PMC article.
Clinical Characteristics of Steatotic Liver Disease Categories in a Large Cohort of Japanese Health Checkup Participants.
Kamada Y, Fujii H, Suzuki Y, Sawada K, Tatsuta M, Maeshiro T, Tobita H, Tsutsumi T, Akahane T, Hasebe C, Kawanaka M, Kessoku T, Eguchi Y, Syokita H, Nakajima A, Kamada T, Yoshiji H, Kawaguchi T, Sakugawa H, Morishita A, Masaki T, Ohmura T, Watanabe T, Yoda Y, Enomoto N, Ono M, Fuyama K, Okada K, Nishimoto N, Ito YM, Takahashi H, Sumida Y; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Kamada Y, et al. Among authors: fujii h. Gastro Hep Adv. 2024 Aug 10;3(8):1148-1156. doi: 10.1016/j.gastha.2024.08.006. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39559296 Free PMC article.
Is liver fibrosis more advanced in MetALD than in MASLD?
Fujii H, Kamada Y, Tokushige A, Watanabe T, Kawada N. Fujii H, et al. J Hepatol. 2025 Jan;82(1):e56-e57. doi: 10.1016/j.jhep.2024.07.028. Epub 2024 Jul 29. J Hepatol. 2025. PMID: 39084472 No abstract available.
Predictors of Immediate Deterioration of the Child-Pugh Classification From A to B After Transcatheter Arterial Chemo-Embolization for Treatment-Naive Hepatocellular Carcinoma.
Asano K, Kageyama K, Yamamoto A, Jogo A, Nakano M, Murai K, Yukawa-Muto Y, Odagiri N, Kotani K, Kozuka R, Kawamura E, Fujii H, Uchida-Kobayashi S, Enomoto M, Kawada N, Miki Y. Asano K, et al. Among authors: fujii h. Cancer Med. 2024 Nov;13(21):e70367. doi: 10.1002/cam4.70367. Cancer Med. 2024. PMID: 39487694 Free PMC article.
Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review.
Kamada Y, Sumida Y, Takahashi H, Fujii H, Miyoshi E, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD). Kamada Y, et al. Among authors: fujii h. J Gastroenterol. 2025 Jan;60(1):10-23. doi: 10.1007/s00535-024-02179-8. Epub 2024 Dec 9. J Gastroenterol. 2025. PMID: 39652103 Review.
4,055 results